ZAI LAB LTD (ZLAB)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$24.03+9.03%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge ZAI LAB LTD’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	113.57M
EPS	—	-0.618
Annual ending 2026-12-31
Revenue	—	421.64M
EPS	—	-2.223
Annual ending 2027-12-31
Revenue	—	515.67M
EPS	—	-2.148

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Improve cash from operations to reduce cash burn	Cash flow is improving, with operating cash burn down to $12 million in Q1 2026.	Broken	cash burn worsens beyond -$12 million next year	Cash from operations: $-63.406M FY2026-Q2; GAAP. Published target: cash burn no worse than -$12 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-63,406,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain stable leadership to execute strategy	A supporting condition in ZAI LAB LTD's published investment case. The stated target is no further major leadership departures.	Under Pressure	additional senior leadership departures occur	1 senior departure vs 0 allowed Form 8-K reports President and COO Josh Smiley leaving his roles on May 21, 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce operating losses and improve operating income over time	A primary condition in ZAI LAB LTD's published investment case. The stated target is operating loss less negative than -$69.4 million.	Broken	operating loss worsens beyond -$69.4 million next year	Operating income: $-76.489M FY2026-Q2; GAAP. Published target: operating loss less negative than -$69.4 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-76,489,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 16df4a6e-16c2-4912-beb9-b19414119f1e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Grow total revenue to at least $460 million in 2026	Zai Lab aims to grow revenue to about $460 million in 2026.	Intact	revenue falls below $460 million in FY26	Revenue: $106.311M FY2026-Q2; GAAP. Published target: >= $460 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026106,311,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 16df4a6e-16c2-4912-beb9-b19414119f1e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.15

$-1.69 → $-2.15 · observed estimates

FY2027 revenue$0.52B

$0.57B → $0.52B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.69	$565,534,707	7 / 11
2026-07-25	$-1.75	$595,574,470	10 / 16
2026-07-26	$-1.75	$595,574,470	10 / 16
2026-07-27	$-1.69	$565,534,707	7 / 11
2026-07-28	$-1.70	$564,330,278	7 / 11
2026-07-29	$-1.70	$564,330,278	7 / 11
2026-07-30	$-1.76	$594,595,880	10 / 16
2026-07-31	$-1.64	$563,426,693	7 / 11
2026-08-01	$-1.64	$563,426,693	7 / 11
2026-08-02	$-1.76	$594,595,880	10 / 16
2026-08-03	$-1.76	$594,595,880	10 / 16
2026-08-04	$-1.64	$563,426,693	7 / 11
2026-08-05	$-1.64	$563,426,693	7 / 11
2026-08-06	$-1.64	$563,426,693	7 / 11
2026-08-08	$-1.64	$563,426,693	7 / 11
2026-08-09	$-1.64	$563,426,693	7 / 11
2026-08-10	$-1.64	$563,426,693	7 / 11
2026-08-12	$-2.06	$572,560,850	10 / 16
2026-08-13	$-1.64	$563,426,693	7 / 11
2026-08-14	$-1.64	$563,426,693	7 / 11
2026-08-15	$-1.64	$563,426,693	7 / 11
2026-08-16	$-1.64	$563,426,693	7 / 11
2026-08-17	$-1.64	$563,426,693	7 / 11
2026-08-18	$-1.64	$563,426,693	7 / 11
2026-08-19	$-1.64	$563,426,693	7 / 11
2026-08-20	$-2.06	$522,742,477	7 / 12
2026-08-21	$-2.06	$522,742,477	7 / 12
2026-08-22	$-2.06	$522,742,477	7 / 12
2026-08-23	$-2.06	$522,742,477	7 / 12
2026-08-24	$-2.06	$522,742,477	7 / 12
2026-08-25	$-2.09	$520,689,443	7 / 12
2026-08-26	$-2.09	$520,689,443	7 / 12
2026-08-27	$-2.09	$520,689,443	7 / 12
2026-08-28	$-2.09	$520,689,443	7 / 12
2026-08-29	$-2.13	$517,407,453	7 / 12
2026-08-30	$-2.13	$517,407,453	7 / 12
2026-08-31	$-2.13	$517,407,453	7 / 12
2026-09-01	$-2.13	$517,407,453	7 / 12
2026-09-02	$-2.13	$517,407,453	7 / 12
2026-09-03	$-2.13	$517,407,453	7 / 12
2026-09-04	$-2.13	$517,407,453	7 / 12
2026-09-05	$-2.13	$517,407,453	7 / 12
2026-09-06	$-2.13	$517,407,453	7 / 11
2026-09-07	$-2.13	$517,407,453	7 / 11
2026-09-08	$-2.13	$517,407,453	7 / 11
2026-09-09	$-2.13	$517,407,453	6 / 11
2026-09-10	$-2.13	$517,407,453	6 / 11
2026-09-11	$-2.13	$517,407,453	6 / 11
2026-09-12	$-2.13	$517,407,453	6 / 11
2026-09-13	$-2.13	$517,407,453	6 / 11
2026-09-14	$-2.13	$517,407,453	6 / 11
2026-09-15	$-2.13	$517,407,453	6 / 11
2026-09-16	$-2.13	$517,407,453	6 / 11
2026-09-17	$-2.13	$517,407,453	6 / 11
2026-09-18	$-2.13	$517,407,453	6 / 11
2026-09-19	$-2.13	$517,407,453	6 / 11
2026-09-20	$-2.15	$515,669,564	6 / 11
2026-09-21	$-2.15	$515,669,564	6 / 11
2026-09-22	$-2.15	$515,669,564	6 / 11
2026-09-23	$-2.15	$515,669,564	6 / 11
2026-09-24	$-2.15	$515,669,564	6 / 11
2026-09-25	$-2.15	$515,669,564	6 / 11
2026-09-26	$-2.15	$515,669,564	6 / 11
2026-09-27	$-2.15	$515,669,564	6 / 11
2026-09-28	$-2.15	$515,669,564	6 / 11
2026-09-29	$-2.15	$515,669,564	6 / 11
2026-09-30	$-2.15	$515,669,564	6 / 11
2026-10-01	$-2.15	$515,669,564	6 / 11
2026-10-02	$-2.15	$515,669,564	6 / 11
2026-10-03	$-2.15	$515,669,564	6 / 11
2026-10-04	$-2.15	$515,669,564	6 / 11
2026-10-05	$-2.15	$515,669,564	6 / 11
2026-10-06	$-2.15	$515,669,564	6 / 11
2026-10-07	$-2.15	$515,669,564	6 / 11
2026-10-08	$-2.15	$515,669,564	6 / 11
2026-10-09	$-2.15	$515,669,564	6 / 11
2026-10-10	$-2.15	$515,669,564	6 / 11
2026-10-11	$-2.15	$515,669,564	6 / 11
2026-10-12	$-2.15	$515,669,564	6 / 11
2026-10-13	$-2.15	$515,669,564	6 / 11
2026-10-14	$-2.15	$515,669,564	6 / 11
2026-10-15	$-2.15	$515,669,564	6 / 11
2026-10-16	$-2.15	$515,669,564	6 / 11
2026-10-17	$-2.15	$515,669,564	6 / 11
2026-10-18	$-2.15	$515,669,564	6 / 11
2026-10-19	$-2.15	$515,669,564	6 / 11
2026-10-20	$-2.15	$515,669,564	6 / 11
2026-10-21	$-2.15	$515,669,564	6 / 11
2026-10-22	$-2.15	$515,669,564	6 / 11
2026-10-23	$-2.15	$515,669,564	6 / 11
2026-10-24	$-2.15	$515,669,564	6 / 11

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	11	1
2026-06-01	11	1
2026-07-01	11	1
2026-08-01	11	1
2026-09-01	11	1
2026-10-01	11	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improve cash from operations to reduce cash burnPublished status: Broken
Maintain stable leadership to execute strategyPublished status: Under Pressure
Reduce operating losses and improve operating income over timePublished status: Broken
Grow total revenue to at least $460 million in 2026Revenue: $106.311M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.7%Typical daily move · historical

Downside history

-41.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

ZAI LAB LTD outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth story built around advancing oncology and immunology products, not a proven earnings compounder. The long-term thesis remains in a watch state: management priorities are clear, but recent financial performance is weak and risk is elevated.

What's priced into ZAI LAB LTD

The valuation model shows ZLAB at a 6.53% premium to peers, with low model confidence and an expectations gap of 3.4. The evidence points to an expensive valuation, but not a full combination of expensive, weak, and turbulent conditions; expectations tied to pipeline optionality appear to be part of the case.

What the fundamentals likely do

Near term, results may remain pressured: second-quarter revenue rose sequentially but was below the year-earlier quarter, and operating loss widened from the prior quarter. Management continues to advance the pipeline and expand China access, but year-over-year revenue comparisons remain lower, so progress toward the stated return to growth in 2027 is not yet established. A guidance cut is a key near-term risk, while the broader healthcare sector backdrop has improved.

What ZAI LAB LTD hinges on

The multi-year view hinges on pipeline progress, stabilization of product sales, and successful commercial launches in China, including KarXT. Near term, a guidance cut or further weakening in jobs data could add pressure, while continued strong results and guidance from healthcare peers could support sector momentum. Recent private-placement and unregistered equity-sale notices add a capital-allocation item to monitor, but the snapshot gives limited detail on their effects.

Bottom line

Over the next 1 to 3 years, ZLAB’s thesis has meaningful pipeline and commercial execution potential, but the evidence so far shows limited financial progress and an expensive valuation. The main test is whether launches and pipeline work translate into steadier revenue without further weakening in guidance. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	113.57M
EPS	—	-0.618
Annual ending 2026-12-31
Revenue	—	421.64M
EPS	—	-2.223
Annual ending 2027-12-31
Revenue	—	515.67M
EPS	—	-2.148

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.15

$-1.69 → $-2.15 · observed estimates

FY2027 revenue$0.52B

$0.57B → $0.52B · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.69	$565,534,707	7 / 11
2026-07-25	$-1.75	$595,574,470	10 / 16
2026-07-26	$-1.75	$595,574,470	10 / 16
2026-07-27	$-1.69	$565,534,707	7 / 11
2026-07-28	$-1.70	$564,330,278	7 / 11
2026-07-29	$-1.70	$564,330,278	7 / 11
2026-07-30	$-1.76	$594,595,880	10 / 16
2026-07-31	$-1.64	$563,426,693	7 / 11
2026-08-01	$-1.64	$563,426,693	7 / 11
2026-08-02	$-1.76	$594,595,880	10 / 16
2026-08-03	$-1.76	$594,595,880	10 / 16
2026-08-04	$-1.64	$563,426,693	7 / 11
2026-08-05	$-1.64	$563,426,693	7 / 11
2026-08-06	$-1.64	$563,426,693	7 / 11
2026-08-08	$-1.64	$563,426,693	7 / 11
2026-08-09	$-1.64	$563,426,693	7 / 11
2026-08-10	$-1.64	$563,426,693	7 / 11
2026-08-12	$-2.06	$572,560,850	10 / 16
2026-08-13	$-1.64	$563,426,693	7 / 11
2026-08-14	$-1.64	$563,426,693	7 / 11
2026-08-15	$-1.64	$563,426,693	7 / 11
2026-08-16	$-1.64	$563,426,693	7 / 11
2026-08-17	$-1.64	$563,426,693	7 / 11
2026-08-18	$-1.64	$563,426,693	7 / 11
2026-08-19	$-1.64	$563,426,693	7 / 11
2026-08-20	$-2.06	$522,742,477	7 / 12
2026-08-21	$-2.06	$522,742,477	7 / 12
2026-08-22	$-2.06	$522,742,477	7 / 12
2026-08-23	$-2.06	$522,742,477	7 / 12
2026-08-24	$-2.06	$522,742,477	7 / 12
2026-08-25	$-2.09	$520,689,443	7 / 12
2026-08-26	$-2.09	$520,689,443	7 / 12
2026-08-27	$-2.09	$520,689,443	7 / 12
2026-08-28	$-2.09	$520,689,443	7 / 12
2026-08-29	$-2.13	$517,407,453	7 / 12
2026-08-30	$-2.13	$517,407,453	7 / 12
2026-08-31	$-2.13	$517,407,453	7 / 12
2026-09-01	$-2.13	$517,407,453	7 / 12
2026-09-02	$-2.13	$517,407,453	7 / 12
2026-09-03	$-2.13	$517,407,453	7 / 12
2026-09-04	$-2.13	$517,407,453	7 / 12
2026-09-05	$-2.13	$517,407,453	7 / 12
2026-09-06	$-2.13	$517,407,453	7 / 11
2026-09-07	$-2.13	$517,407,453	7 / 11
2026-09-08	$-2.13	$517,407,453	7 / 11
2026-09-09	$-2.13	$517,407,453	6 / 11
2026-09-10	$-2.13	$517,407,453	6 / 11
2026-09-11	$-2.13	$517,407,453	6 / 11
2026-09-12	$-2.13	$517,407,453	6 / 11
2026-09-13	$-2.13	$517,407,453	6 / 11
2026-09-14	$-2.13	$517,407,453	6 / 11
2026-09-15	$-2.13	$517,407,453	6 / 11
2026-09-16	$-2.13	$517,407,453	6 / 11
2026-09-17	$-2.13	$517,407,453	6 / 11
2026-09-18	$-2.13	$517,407,453	6 / 11
2026-09-19	$-2.13	$517,407,453	6 / 11
2026-09-20	$-2.15	$515,669,564	6 / 11
2026-09-21	$-2.15	$515,669,564	6 / 11
2026-09-22	$-2.15	$515,669,564	6 / 11
2026-09-23	$-2.15	$515,669,564	6 / 11
2026-09-24	$-2.15	$515,669,564	6 / 11
2026-09-25	$-2.15	$515,669,564	6 / 11
2026-09-26	$-2.15	$515,669,564	6 / 11
2026-09-27	$-2.15	$515,669,564	6 / 11
2026-09-28	$-2.15	$515,669,564	6 / 11
2026-09-29	$-2.15	$515,669,564	6 / 11
2026-09-30	$-2.15	$515,669,564	6 / 11
2026-10-01	$-2.15	$515,669,564	6 / 11
2026-10-02	$-2.15	$515,669,564	6 / 11
2026-10-03	$-2.15	$515,669,564	6 / 11
2026-10-04	$-2.15	$515,669,564	6 / 11
2026-10-05	$-2.15	$515,669,564	6 / 11
2026-10-06	$-2.15	$515,669,564	6 / 11
2026-10-07	$-2.15	$515,669,564	6 / 11
2026-10-08	$-2.15	$515,669,564	6 / 11
2026-10-09	$-2.15	$515,669,564	6 / 11
2026-10-10	$-2.15	$515,669,564	6 / 11
2026-10-11	$-2.15	$515,669,564	6 / 11
2026-10-12	$-2.15	$515,669,564	6 / 11
2026-10-13	$-2.15	$515,669,564	6 / 11
2026-10-14	$-2.15	$515,669,564	6 / 11
2026-10-15	$-2.15	$515,669,564	6 / 11
2026-10-16	$-2.15	$515,669,564	6 / 11
2026-10-17	$-2.15	$515,669,564	6 / 11
2026-10-18	$-2.15	$515,669,564	6 / 11
2026-10-19	$-2.15	$515,669,564	6 / 11
2026-10-20	$-2.15	$515,669,564	6 / 11
2026-10-21	$-2.15	$515,669,564	6 / 11
2026-10-22	$-2.15	$515,669,564	6 / 11
2026-10-23	$-2.15	$515,669,564	6 / 11
2026-10-24	$-2.15	$515,669,564	6 / 11

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings